TABLE 1.
Characteristics of COVID‐19 patients with or without diagnosis of acute heart failure (n (%) or median [IQR])
| Heart failure n = 3 | No heart failure n = 13 | P | ||
|---|---|---|---|---|
| Demographic characteristics | Female | 1 (33%) | 9 (69%) | 0.5 |
| Age | 86 [81–92] | 89 [83–92] | 0.6 | |
| Clinical data | Cough | 2 (66%) | 9 (69%) | 1 |
| Dyspnoea | 3 (100%) | 13 (100%) | 1 | |
| Chest pain | 0 (0%) | 0 (0%) | 1 | |
| Anosmia, ageusia, dysgeusia | 0 (0%) | 2 (15%) | 1 | |
| Asthenia | 3 (100%) | 13 (100%) | 1 | |
| Abdominal pain | 1 (33%) | 4 (30%) | 1 | |
| Diarrhoea | 2 (66%) | 7 (54%) | 1 | |
| Temperature (°C) | 38 [38–38] | 38 [37.8–38.4] | 0.3 | |
| Respiratory rate (/min) | 20 [20–22] | 24 [24–30] | 0.03 | |
| Oxygen saturation (%) | 94 [93–96] | 93 [93–95] | 0.7 | |
| Heart rate (/min) | 75 [75–90] | 78 [70–83] | 0.3 | |
| Systolic blood pressure (mmHg) | 131 [129–133] | 124 [110–141] | 0.8 | |
| Diastolic blood pressure (mmHg) | 74 [66–76] | 65 [59–81] | 0.7 | |
| Pulmonary condensation syndrome | 1 (33%) | 3 (23%) | 1 | |
| Right heart failure | 2 (66%) | 5 (38%) | 0.6 | |
| Left heart failure | 2 (66%) | 0 (0%) | 0.02 | |
| Biological data | Leucocytes (cells/μL) | 9,400 [9,250‐10,550] | 5,700 [4,500‐9,400] | 0.6 |
| Lymphocytes (cells/μL) | 790 [680–1,245] | 1,030 [620–1,390] | 0.8 | |
| Platelets (1000 cells/μL) | 248 [202–292] | 166 [123–184] | 0.2 | |
| C‐reactive protein (mg/dL) | 167 [102–177] | 49 [21–91] | 0.2 | |
| Procalcitonin rate (μg/L) | 0.28 [0.22–0.34] | 0.25 [0.17–0.53] | 0.3 | |
| Troponin I (μg/L) | 0.52 [0.37–0.67] | 0.04 [0.02–0.08] | 0.4 | |
| NT‐proBNP (pmol/L) | 5,609 [4,319‐6,900] | 677 [427–1,800] | 0.3 | |
| Creatinine (μmol/L) | 94 [79–88] | 75 [59–145] | 0.4 | |
| Uraemia (mmol/L) | 13 [11–18] | 10 [8.6–13.9] | 0.4 | |
| Ultrasound | LEVF >50% | 2 (66%) | 4 (31%) | 0.5 |
| E/A >1 | 1 (33%) | 0 (0%) | 0.18 | |
| Enlarged IVC | 3 (100%) | 0 (0%) | 0.002 | |
| Right auricle enlargement | 1 (33%) | 0 (8%) | 0.2 | |
| Sub‐pleural consolidation | 0 (0%) | 4 (31%) | 0.5 | |
| Pleural effusion | 1 (33%) | 3 (23%) | 1 | |
| B Lines | 3 (100%) | 9 (69%) | 0.5 | |
| Heart failure diagnosis | 3 (100%) | 0 (0%) | 0.002 | |
| CT‐Scan | Sub‐pleural consolidation | 2 (66%) | 6 (46%) | 1 |
| Pleural effusion | 0 (0%) | 2 (15%) | 1 | |
| Fibrosis | 0 (0%) | 2 (15%) | 1 | |
| Crazy paving | 1 (33%) | 3 (23%) | 1 | |
| Grounding glass opacity | 2 (66%) | 6 (46%) | 1 | |
| Heart chambers enlargement | 1 (33%) | 2 (15%) | 0.5 | |
| Outcome | Death rate | 1 (33%) | 3 (23%) | 1 |
| Hospitalization length (days) | 15 [9–22] | 10 [6–15] | 0.6 |
LEVF, left ventricular ejection fraction; NT‐ProBNP, N terminal pro brain natriuretic peptide.